Advertisement

Physiopathology, Diagnosis, and Treatment of Secondary Hyperthyroidism

  • Paolo Beck-Peccoz
  • Claudia Giavoli
  • Giulia Rodari
  • Andrea Lania
Reference work entry
Part of the Endocrinology book series (ENDOCR)

Abstract

Thyrotropin-secreting pituitary adenomas (TSHomas) are a rare cause of secondary hyperthyroidism and account for less than 2% of all pituitary adenomas. In the last 30 years, the recognition of TSHomas has been facilitated by the routine use of ultrasensitive TSH immunometric assays, i.e., methods clearly able to distinguish between TSH concentration in normal controls and undetectable TSH levels in hyperthyroid patients, as well as by the direct measurement of circulating free thyroid hormones (FT4 and FT3). TSHomas must be promptly diagnosed whenever measurable levels of TSH in the presence of high FT4 and FT3 concentrations are documented. As similar biochemical picture is found in patients with thyroid hormone resistance (RTH), a differential diagnosis between the two disorders must be performed. Therefore, a correct diagnosis is fundamental in order to prevent dramatic consequences, such as improper thyroidectomy in patients with secondary hyperthyroidism due to TSHoma or unnecessary pituitary surgery in patients with RTH. The differential diagnosis between TSHomas and RTH mainly rests on dynamic testing, such as T3 suppression test, TRH tests, as well as injection of long acting somatostatin for 2 or more months.

First-line therapeutical approach to TSHomas remains pituitary neurosurgery, though in particular cases medical treatment should be considered. The medical treatment of TSHomas mainly rests on the administration of somatostatin analogs, such as octreotide and lanreotide, which are effective in reducing TSH secretion in the majority of patients with consequent normalization of FT4 and FT3 levels and restoration of the euthyroid state.

Keywords

Thyroid hyperfunction TSH-induced TSH-secreting pituitary adenomas (TSHomas) Resistance to thyroid hormones Thyrotropin (thyroid-stimulating hormone, TSH) Pituitary glycoprotein hormone α-subunit (α-GSU) Somatostatin analogs (octreotide, lanreotide) Dopaminergic drugs (cabergoline, bromocriptine) 

References

  1. Abs R, Stevenaert A, Beckers A. Autonomously functioning thyroid nodules in a patient with a thyrotropin-secreting pituitary adenoma: possible cause-effect relationship. Eur J Endocrinol. 1994;131:355–8.PubMedCrossRefGoogle Scholar
  2. Ando S, Sarlis NJ, Krishnan J, Feng X, Refetoff S, Zhang MQ, Oldfield EH, Yen PM. Aberrant alternative splicing of thyroid hormone receptor in a TSH-secreting pituitary tumor is a mechanism for hormone resistance. Mol Endocrinol. 2001a;15:1529–38.PubMedCrossRefGoogle Scholar
  3. Ando S, Sarlis NJ, Oldfield EH, Yen PM. Somatic mutation of TRbeta can cause a defect in negative regulation of TSH in a TSH-secreting pituitary tumor. J Clin Endocrinol Metab. 2001b;86: 5572–6.PubMedGoogle Scholar
  4. Asa SL, Puy LA, Lew AM, Sundmark VC, Elsholtz HP. Cell type-specific expression of the pituitary transcription activator pit-1 in the human pituitary and pituitary adenomas. J Clin Endocrinol Metab. 1993;77:1275–80.PubMedGoogle Scholar
  5. Asteria C, Anagni M, Persani L, Beck-Peccoz P. Loss of heterozigosity of the MEN1 gene in a large series of TSH-secreting pituitary adenomas. J Endocrinol Investig. 2001;24:796–801.CrossRefGoogle Scholar
  6. Azzalin A, Appin CL, Schniederjan MJ, Constantin T, Ritchie JC, Veledar E, Oyesiku NM, Ioachimescu AG. Comprehensive evaluation of thyrotropinomas: single-center 20-year experience. Pituitary. 2016;19:183–93.PubMedCrossRefGoogle Scholar
  7. Banerjee AK, Sharma BS, Kak VK. Clinically and biochemically silent thyrotroph adenoma with oncocytic change. Neurol India. 2000;48:374–7.PubMedGoogle Scholar
  8. Barlier A, Vanbellinghen JF, Daly AF, Silvy M, Jaffrain-Rea ML, Trouillas J, Tamagno G, Cazabat L, Bours V, Brue T, Enjalbert A, Beckers A. Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. J Clin Endocrinol Metab. 2007;92:1952–5.PubMedCrossRefGoogle Scholar
  9. Beck-Peccoz P, Persani L. Variable biological activity of thyroid-stimulating hormone. Eur J Endocrinol. 1994;131:331–40.PubMedCrossRefGoogle Scholar
  10. Beck-Peccoz P, Mariotti S, Guillausseau PJ, Medri G, Piscitelli G, Bertoli A, Barbarino Rondena AM, Chanson P, Pinchera A. Treatment of hyperthyroidism due to inappropriate secretion of thyrotropin with the somatostatin analog SMS 201-995. J Clin Endocrinol Metab. 1989;68:208–14.PubMedCrossRefGoogle Scholar
  11. Beck-Peccoz P, Roncoroni R, Mariotti S, Medri G, Marcocci C, Brabant G, Forloni F, Pinchera A, Faglia G. Sex hormone-binding globulin measurement in patients with inappropriate secretion of thyrotropin (IST): evidence against selective pituitary thyroid hormone resistance in nonneoplastic IST. J Clin Endocrinol Metab. 1990;71:19–25.PubMedCrossRefGoogle Scholar
  12. Beck-Peccoz P, Persani L, Faglia G. Glycoprotein hormone alpha-subunit in pituitary adenomas. Trends Endocrinol Metab. 1992;3:41–5.PubMedCrossRefGoogle Scholar
  13. Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD. Thyrotropin-secreting pituitary tumors. Endocr Rev. 1996;17:610–38.PubMedGoogle Scholar
  14. Beck-Peccoz P, Lania A, Beckers A, Chatterjee K, Wemeau JL. European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. Eur Thyroid J. 2013;2:76–82.PubMedPubMedCentralCrossRefGoogle Scholar
  15. Beck-Peccoz P, Lania A, Persani L. TSH-producing adenomas. In: Jameson JL, DeGroot LJ, editors. Endocrinology adult and pediatric. 7th ed. Philadelphia: Elsevier Saundres; 2016. p. 266–74.CrossRefGoogle Scholar
  16. Bertherat J, Brue T, Enjalbert A, Gunz G, Rasolonjanahary R, Warnet A, Jaquet P, Epelbaum J. Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions. J Clin Endocrinol Metab. 1992;75:540–6.PubMedGoogle Scholar
  17. Bertholon-Grégoire M, Trouillas J, Guigard MP, Loras B, Tourniaire J. Mono- and plurihormonal thyrotropic pituitary adenomas: pathological, hormonal and clinical studies in 12 patients. Eur J Endocrinol. 1999;140:519–27.PubMedCrossRefGoogle Scholar
  18. Blackhurst G, Strachan MW, Collie D, Gregor A, Statham PF, Seckl JE. The treatment of a thyrotropin-secreting pituitary macroadenoma with octreotide in twin pregnancy. Clin Endocrinol. 2002;57:401–4.CrossRefGoogle Scholar
  19. Brown RL, Muzzafar T, Wollman R, Weiss RE. A pituitary carcinoma secreting TSH and prolactin: a non-secreting adenoma gone awry. Eur J Endocrinol. 2006;154:639–43.PubMedCrossRefGoogle Scholar
  20. Brucker-Davis F, Oldfield EH, Skarulis MC, Doppman JL, Weintraub B. Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab. 1999;84: 476–86.PubMedCrossRefGoogle Scholar
  21. Chaiamnuay S, Moster M, Katz MR, Kim YN. Successful management of a pregnant woman with a TSH secreting pituitary adenoma with surgical and medical therapy. Pituitary. 2003;6:109–13.PubMedCrossRefGoogle Scholar
  22. Chanson P, Orgiazzi J, Derome PJ, Bression D, Jedynak CP, Trouillas J, Legentil P, Racadot J, Peillon F. Paradoxical response of thyrotropin to L-dopa and presence of dopaminergic receptors in a thyrotropin-secreting pituitary adenoma. J Clin Endocrinol Metab. 1984;59:542–6.PubMedCrossRefGoogle Scholar
  23. Chanson P, Weintraub BD, Harris AG. Octreotide therapy for thyroid stimulating-secreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med. 1993;119:236–40.PubMedCrossRefGoogle Scholar
  24. Clarke MJ, Erickson D, Castro MR, Atkinson JLD. Thyroid-stimulating pituitary adenomas. J Neurosurg. 2008;109:17–22.PubMedCrossRefGoogle Scholar
  25. Cohen LE, Radovick S. Molecular bases of pituitary hormone deficiencies. Endocr Rev. 2002;23:431–42.PubMedCrossRefGoogle Scholar
  26. Collie RB, Collie MJ. Extracranial thyroid-stimulating hormone-secreting ectopic pituitary adenoma of the nasopharynx. Otolaryngol Head Neck Surg. 2005;133:453–4.PubMedCrossRefGoogle Scholar
  27. Cooper DS, Wenig BM. Hyperthyroidism caused by an ectopic TSH-secreting pituitary tumor. Thyroid. 1996;6:337–43.PubMedCrossRefGoogle Scholar
  28. Daly AF, Tichomirowa MA, Petrossians P, Heliövaara E, Jaffrain-Rea ML, Barlier A, Naves LA, Ebeling T, Karhu A, Raappana A, Cazabat L, De Menis E, Montañana CF, Raverot G, Weil RJ, Sane T, Maiter D, Neggers S, Yaneva M, Tabarin A, Verrua E, Eloranta E, Murat A, Vierimaa O, Salmela PI, Emy P, Toledo RA, Sabaté MI, Villa C, Popelier M, Salvatori R, Jennings J, Longás AF, Labarta Aizpún JI, Georgitsi M, Paschke R, Ronchi C, Valimaki M, Saloranta C, De Herder W, Cozzi R, Guitelman M, Magri F, Lagonigro MS, Halaby G, Corman V, Hagelstein MT, Vanbellinghen JF, Barra GB, Gimenez-Roqueplo AP, Cameron FJ, Borson-Chazot F, Holdaway I, Toledo SP, Stalla GK, Spada A, Zacharieva S, Bertherat J, Brue T, Bours V, Chanson P, Aaltonen LA, Beckers A. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab. 2010;95:E373–83.PubMedCrossRefGoogle Scholar
  29. Dong Q, Brucker-Davis F, Weintraub BD, Smallridge RC, Carr FE, Battey J, Spiegel AM, Shenker A. Screening of candidate oncogenes in human thyrotroph tumors: absence of activating mutations of the Gαq, Gα11, Gαs, or thyrotropin-releasing hormone receptor genes. J Clin Endocrinol Metab. 1996;81:1134–40.PubMedGoogle Scholar
  30. Ezzat S, Horvath E, Kovacs K, Smyth HS, Singer W, Asa SL. Basic fibroblast growth factor expression by two prolactin and thyrotropin-producing pituitary adenomas. Endocr Pathol. 1995;6:125–34.PubMedCrossRefGoogle Scholar
  31. Filopanti M, Ballaré E, Lania AG, Bondioni S, Verga U, Locatelli M, Zavanone LM, Losa M, Gelmini S, Peri A, Orlando C, Beck-Peccoz P, Spada A. Loss of heterozygosity at the SS receptor type 5 locus in human GH- and TSH-secreting pituitary adenomas. J Endocrinol Investig. 2004;27:937–42.CrossRefGoogle Scholar
  32. Fliers E, van Furth WR, Bisschop PH. Cure of a thyrotrophin (TSH)-secreting pituitary adenoma by medical therapy. Clin Endocrinol. 2012;77:788–90.CrossRefGoogle Scholar
  33. Foppiani L, Ruelle A, Cavazzani P, Del Monte P. TSH-secreting adenomas: rare pituitary tumors with multifaceted clinical and biological features. J Endocrinol Investig. 2007;30:603–9.CrossRefGoogle Scholar
  34. Friedman E, Adams EF, Höög A, Gejman PV, Carson E, Larsson C, De Marco L, Werner S, Fahlbusch R, Nordenskjöld M. Normal structural dopamine type 2 receptor gene in prolactin-secreting and other pituitary tumors. J Clin Endocrinol Metab. 1994;78:568–74.PubMedGoogle Scholar
  35. Gancel A, Vuillermet P, Legrand A, Catus F, Thomas F, Kuhn JM. Effets of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas. Clin Endocrinol. 1994;40:421–8.CrossRefGoogle Scholar
  36. Gasparoni P, Rubello D, Persani L, Beck-Peccoz P. Unusual association between a thyrotropin-secreting pituitary adenoma and a papillary thyroid carcinoma. Thyroid. 1998;8:181–3.PubMedCrossRefGoogle Scholar
  37. Gatto F, Barbieri F, Castelletti L, Arvigo M, Pattarozzi A, Annunziata F, Saveanu A, Minuto F, Castellan L, Zona G, Florio T, Ferone D. In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5. Pituitary. 2011;14:141–7.PubMedCrossRefGoogle Scholar
  38. Gatto F, Grasso LF, Nazzari E, Cuny T, Anania P, Di Somma C, Colao A, Zona G, Weryha G, Pivonello R, Ferone D. Clinical outcome and evidence of high rate post-surgical anterior hypopituitarism in a cohort of TSH-secreting adenoma patients: might somatostatin analogs have a role as first-line therapy? Pituitary. 2015;18:583–91.PubMedCrossRefGoogle Scholar
  39. Gershengorn MC, Weintraub BD. Thyrotropin-induced hyperthyroidism caused by selective pituitary resistance to thyroid hormone. A new syndrome of “inappropriate secretion of TSH”. J Clin Invest. 1975;56:633–42.PubMedPubMedCentralCrossRefGoogle Scholar
  40. Gittoes NJ, McCabe CJ, Verhaeg J, Sheppard MC, Franklyn JA. An abnormality of thyroid hormone receptor expression may explain abnormal thyrotropin production in thyrotropin-secreting pituitary tumors. Thyroid. 1998;8:9–14.PubMedCrossRefGoogle Scholar
  41. Gurnell M, Visser TJ, Beck-Peccoz P, Chatterjee VK. Resistance to thyroid hormone. In: Jameson JL, DeGroot LJ, editors. Endocrinology adult and pediatric. 7th ed. Philadelphia: Elsevier Saundres; 2016. p. 1648–65.CrossRefGoogle Scholar
  42. Horiguchi K, Yamada M, Umezawa R, Satoh T, Hashimoto K, Tosaka M, Yamada S, Mori M. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment. Endocr J. 2007;54:371–8.PubMedCrossRefGoogle Scholar
  43. Idiculla JM, Beckett G, Statham PF, Ironside JW, Atkin SL, Patrick AW. Autoimmune hypothyroidism coexisting with a pituitary adenoma secreting thyroid-stimulating hormone, prolactin and a-subunit. Ann Clin Biochem. 2001;38:566–71.PubMedGoogle Scholar
  44. Iskandar SB, Supit E, Jordan RM, Peiris AN. Thyrotropin-secreting pituitary tumor and Hashimoto’s disease: a novel association. South Med J. 2003;96:933–6.PubMedCrossRefGoogle Scholar
  45. Kamoi K, Mitsuma T, Sato H, Yokoyama M, Washiyama K, Tanaka R, Arai O, Takasu N, Yamada T. Hyperthyroidism caused by a pituitary thyrotrophin-secreting tumour with excessive secretion of thyrotrophin-releasing hormone and subsequently followed by Graves’ disease in a middle-aged woman. Acta Endocrinol. 1985;110:373–82.PubMedGoogle Scholar
  46. Kamoun M, d’Herbomez M, Lemaire C, Fayard A, Desailloud R, Huglo D, Wemeau JL. Coexistence of thyroid-stimulating hormone-secreting pituitary adenoma and Graves’ hyperthyroidism. Eur Thyroid J. 2014;3:60–4.PubMedCrossRefGoogle Scholar
  47. Kienitz T, Quinkler M, Strasburger CJ, Ventz M. Long-term management in five cases of TSH-secreting pituitary adenomas: a single center study and review of the literature. Eur J Endocrinol. 2007;157:39–46.PubMedCrossRefGoogle Scholar
  48. Kirkman MA, Jaunmuktane Z, Brandner S, Khan AA, Powell M, Baldeweg SE. Active and silent thyroid-stimulating hormone-expressing pituitary adenomas: presenting symptoms, treatment, outcomes, and recurrence. World Neurosurg. 2014;82:1224–31.PubMedCrossRefGoogle Scholar
  49. Kishida M, Otsuka F, Kataoka H, Yokota K, Oishi T, Yamauchi T, Doihara H, Tamiya T, Mimura Y, Ogura T, Makino H. Hyperthyroidism in a patient with TSH-producing pituitary adenoma coexisting with thyroid papillary adenocarcinoma. Endocr J. 2000;47:731–8.PubMedCrossRefGoogle Scholar
  50. Koulouri O, Gurnell M. How to interpret thyroid function tests. Clin Med (Lond). 2013;13:282–6.CrossRefGoogle Scholar
  51. Koulouri O, Moran C, Halsall D, Chatterjee K, Gurnell M. Pitfalls in the measurement and interpretation of thyroid function tests. Best Pract Res Clin Endocrinol Metab. 2013;27:745–62.PubMedPubMedCentralCrossRefGoogle Scholar
  52. Kourides IA, Ridgway EC, Weintraub BD, Bigos ST, Gershengorn MC, Maloof F. Thyrotropin-induced hyperthyroidism: use of alpha and beta subunit levels to identify patients with pituitary tumors. J Clin Endocrinol Metab. 1977;45:534–43.PubMedCrossRefGoogle Scholar
  53. Kourides IA, Pekonen F, Weintraub BD. Absence of thyroid-binding immunoglobulins in patients with thyrotropin-mediated hyperthyroidism. J Clin Endocrinol Metab. 1980;51:272–4.PubMedGoogle Scholar
  54. Kuhn JM, Arlot S, Lefebvre H, Caron P, Cortet-Rudelli C, Archambaud F, Chanson P, Tabarin A, Goth MI, Blumberg J, Catus F, Ispas S, Beck-Peccoz P. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. J Clin Endocrinol Metab. 2000;85:1487–91.PubMedCrossRefGoogle Scholar
  55. Langlois MF, Lamarche JB, Bellabarba D. Long-standing goiter and hypothyroidism: an unusual presentation of a TSH-secreting adenoma. Thyroid. 1996;6:329–35.PubMedCrossRefGoogle Scholar
  56. Lee W, Cheung AS, Freilich R. TSH-secreting pituitary carcinoma with intrathecal drop metastase. Clin Endocrinol. 2012;76:604–6.CrossRefGoogle Scholar
  57. Lim EM, Bhagat CI, Walsh J. Asymptomatic thyrotropin-secreting pituitary microadenoma. Intern Med J. 2001;31:428–9.PubMedCrossRefGoogle Scholar
  58. Losa M, Giovanelli M, Persani L, Mortini P, Faglia G, Beck-Peccoz P. Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab. 1996;81:3086–90.Google Scholar
  59. Losa M, Magnani P, Mortini P, Persani L, Acerno S, Giugni E, Songini C, Fazio F, Beck-Peccoz P, Giovanelli M. Indium-111 pentetreotide single-photon emission tomography in patients with TSH-secreting pituitary adenomas: correlation with the effect of a single administration of octreotide on serum TSH levels. Eur J Nucl Med. 1997;24:728–31.PubMedGoogle Scholar
  60. Losa M, Mortini P, Minelli R, Giovanelli M. Coexistence of TSH-secreting pituitary adenoma and autoimmune hypothyroidism. J Endocrinol Investig. 2006;29:555–9.CrossRefGoogle Scholar
  61. Lu C, Willingham MC, Furuya F, Cheng SY. Activation of phosphatidylinositol 3-kinase signaling promotes aberrant pituitary growth in a mouse model of thyrois-stimulating hormone-secreting pituitary tumors. Endocrinology. 2008;149:3339–45.PubMedPubMedCentralCrossRefGoogle Scholar
  62. Ma W, Ikeda H, Watabe N, Kanno M, Yoshimoto T. A plurihormonal TSH-producing pituitary tumor of monoclonal origin in a patient with hypothyroidism. Horm Res. 2003;59:257–61.PubMedGoogle Scholar
  63. Malchiodi E, Profka E, Ferrante E, Sala E, Verrua E, Campi I, Lania AG, Arosio M, Locatelli M, Mortini P, Losa M, Motti E, Beck-Peccoz P, Spada A, Mantovani G. Thyrotropin-secreting pituitary adenomas: outcome of pituitary surgery and irradiation. J Clin Endocrinol Metab. 2014;99:2069–76.PubMedCrossRefGoogle Scholar
  64. Mannavola D, Persani L, Vannucchi G, Zanardelli M, Fugazzola L, Verga U, Facchetti M, Beck-Peccoz P. Different response to chronic somatostatin analogues in patients with central hyperthyroidism. Clin Endocrinol. 2005;62:176–81.CrossRefGoogle Scholar
  65. Mantovani G, Asteria C, Pellegrini C, Bosari S, Alberti L, Bondioni S, Peverelli E, Spada A, Beck-Peccoz P. HESX1 expression in human normal pituitaries and pituitary adenomas. Mol Cell Endocrinol. 2006;247:135–9.PubMedCrossRefGoogle Scholar
  66. Mixson AJ, Friedman TC, Katz DA, Feuerstein IM, Taubenberger JK, Colandrea JM, Doppman JL, Oldfield EH, Weintraub BD. Thyrotropin-secreting pituitary carcinoma. J Clin Endocrinol Metab. 1993;76:529–33.PubMedGoogle Scholar
  67. Mouslech Z, Somali M, Sakali AK, Savopoulos C, Mastorakos G, Hatzitolios AI. TSH-secreting pituitary adenomas treated by gamma knife radiosurgery: our case experience and a review of the literature. Hormones (Athens). 2016;15:122–8.Google Scholar
  68. Mulinda JR, Hasinski S, Rose LI. Successful therapy for a mixed thyrotropin-and prolactin-secreting pituitary macroadenoma with cabergoline. Endocr Pract. 1999;5:76–9.PubMedCrossRefGoogle Scholar
  69. Nakayama Y, Jinguji S, Kumakura S, Nagasaki K, Natsumeda M, Yoneoka Y, Saito T, Fujii Y. Thyroid-stimulating hormone (thyrotropin)-secretion pituitary adenoma in an 8-year-old boy: case report. Pituitary. 2012;15:110–5.PubMedCrossRefGoogle Scholar
  70. Ness-Abramof R, Ishay A, Harel G, Sylvetzky N, Baron E, Greenman Y, Shimon I. TSH-secreting pituitary adenomas. Pituitary. 2007;10:307–10.PubMedCrossRefGoogle Scholar
  71. Ohki M, Sato K, Tuchiya D, Sato S, Saito S, Kinjo T, Kayama T, Jokura H, Yoshimoto T. A case of TSH-secreting pituitary adenoma associated with an unruptured aneurysm: successful treatment by two-stage operation and gamma knife. No To Shinkei. 1999;51:895–9.PubMedGoogle Scholar
  72. Ohta S, Nishizawa S, Oki Y, Namba H. Coexistence of thyrotropin-producing pituitary adenoma with papillary adenocarcinoma of the thyroid: a case report and surgical strategy. Pituitary. 2001;4:271–4.PubMedCrossRefGoogle Scholar
  73. Ónnestam L, Berinder K, Burman P, Dahlqvist P, Engström BE, Wahlberg J, Nyström HF. National incidence and prevalence of TSH-secreting pituitary adenomas in Sweden. J Clin Endocrinol Metab. 2013;98:626–35.PubMedCrossRefGoogle Scholar
  74. Orme SM, Lamb JT, Nelson M, Belchetz PE. Shrinkage of thyrotrophin secreting pituitary adenoma treated with octreotide. Postgrad Med J. 1991;67:466–8.PubMedPubMedCentralCrossRefGoogle Scholar
  75. Pasquini E, Faustini-Fustini M, Sciarretta V, Saggese D, Roncaroli F, Serra D, Frank G. Ectopic TSH-secreting pituitary adenoma of the vomerosphenoidal junction. Eur J Endocrinol. 2003;148:253–7.PubMedCrossRefGoogle Scholar
  76. Pellegrini-Bouiller I, Morange-Ramos I, Barlier A, Gunz G, Enjalbert A, Jaquet P. Pit-1 gene expression in human pituitary adenomas. Horm Res. 1997;47:251–8.PubMedCrossRefGoogle Scholar
  77. Pereira BD, Raimundo L, Mete O, Oliveira A, Portugal J, Asa SL. Monomorphous plurihormonal pituitary adenoma of pit-1 lineage in a giant adolescent with central hyperthyroidism. Endocr Pathol. 2016;27:25–33.PubMedCrossRefGoogle Scholar
  78. Persani L, Preziati D, Matthews CH, Sartorio A, Chatterjee VK, Beck-Peccoz P. Serum levels of carboxyterminal cross-linked telopeptide of type I collagen (ICTP) in the differential diagnosis of the syndromes of inappropriate secretion of TSH. Clin Endocrinol. 1997;47:207–14.CrossRefGoogle Scholar
  79. Poggi M, Monti S, Pascucci C, Toscano V. A rare case of follicular thyroid carcinoma in a patient with thyrotropin-secreting pituitary adenoma. Am J Med Sci. 2009;337:462–5.PubMedCrossRefGoogle Scholar
  80. Raappana A, Koivukangas J, Ebeling T, Pirilä T. Incidence of pituitary adenomas in Northern Finland in 1992–2007. J Clin Endocrinol Metab. 2010;95:4268–75.PubMedCrossRefGoogle Scholar
  81. Rabbiosi S, Peroni E, Tronconi GM, Chiumello G, Losa M, Weber G. Asymptomatic thyrotropin-secreting pituitary macroadenoma in a 13-year-old girl: successful first-line treatment with somatostatin analogs. Thyroid. 2012;22:1076–9.PubMedCrossRefGoogle Scholar
  82. Refetoff S, Weiss RE, Usala SJ. The syndromes of resistance to thyroid hormone. Endocr Rev. 1993;14:348–99.PubMedGoogle Scholar
  83. Rimareix F, Grunenwald S, Vezzosi D, Rivière LD, Bennet A, Caron P. Primary medical treatment of thyrotropin-secreting pituitary adenomas by first-generation somatostatin analogs: a case study of seven patients. Thyroid. 2015;25:877–82.PubMedCrossRefGoogle Scholar
  84. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science. 2000;288:154–7.PubMedCrossRefGoogle Scholar
  85. Roelfsema F, Pereira AM, Keenan DM, Veldhuis JD, Romijn JA. Thyrotropin secretion by thyrotropinomas is characterized by increased pulse frequency, delayed diurnal rhythm, enhanced basal secretion, spikiness, and disorderliness. J Clin Endocrinol Metab. 2008;93: 4052–7.PubMedCrossRefGoogle Scholar
  86. Safer JD, Colan SD, Fraser LM, Wondisford FE. A pituitary tumor in a patient with thyroid hormone resistance: a diagnostic dilemma. Thyroid. 2001;11:281–91.PubMedCrossRefGoogle Scholar
  87. Sato S, Kanai N, Kanai H, Sugase T, Hanada M, Hayakawa T, Saito Y, Oonishi T, Oda Y, Miyagawa J. TSH-secreting fibrous pituitary adenoma showing calcification: a case report. No Shinkei Geka. 1995;23:259–63.PubMedGoogle Scholar
  88. Socin HV, Chanson P, Delemer B, Tabarin A, Rohmer V, Mockel J, Stevenaert A, Beckers A. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol. 2003;148:433–42.PubMedCrossRefGoogle Scholar
  89. Song M, Wang H, Song L, Tian H, Ge Q, Li J, Zhu Y, Li J, Zhao R, Ji HL. Ectopic TSH-secreting pituitary tumor: a case report and review of prior cases. BMC Cancer. 2014;14:544–7.PubMedPubMedCentralCrossRefGoogle Scholar
  90. Spada A, Bassetti M, Martino E, Giannattasio G, Beck-Peccoz P, Sartorio A, Vallar L, Baschieri L, Pinchera A, Faglia G. In vitro studies on TSH secretion and adenylate cyclase activity in a human TSH-secreting pituitary adenoma. Effects of somatostatin and dopamine. J Endocrinol Investig. 1985;8:193–8.CrossRefGoogle Scholar
  91. Schoenmakers N, Moran C, Campi I, Agostini M, Bacon O, Rajanayagam O, Schwabe J, Bradbury S, Barrett T, Geoghegan F, Druce M, Beck-Peccoz P, O’ Toole A, Clark P, Bignell M, Lyons G, Halsall D, Gurnell M, Chatterjee K. A novel albumin gene mutation (R222I) in familial dysalbuminemic hyperthyroxinemia. J Clin Endocrinol Metab. 2014;99:E1381–6.Google Scholar
  92. Tagami T, Usui T, Shimatsu A, Beniko M, Yamamoto H, Moriyama K, Naruse M. Aberrant expression of thyroid hormone receptor beta isoform may cause inappropriate secretion of TSH in a TSH-secreting pituitary adenoma. J Clin Endocrinol Metab. 2011;96:E948–52.PubMedCrossRefGoogle Scholar
  93. Taylor TJ, Donlon SS, Bale AE, Smallridge RC, Francis TB, Christensen RS, Burma KD. Treatment of a thyrotropinoma with octreotide-LAR in a patient with multiple endocrine neoplasia-1. Thyroid. 2000;10:1001–7.PubMedCrossRefGoogle Scholar
  94. Teng X, Jin T, Brent GA, Wu A, Teng W, Shan Z. A patient with a thyrotropin-secreting microadenoma and resistance to thyroid hormone (P453T). J Clin Endocrinol Metab. 2015;100:2511–4.PubMedPubMedCentralCrossRefGoogle Scholar
  95. Terzolo M, Orlandi F, Bassetti M, Medri G, Paccotti P, Cortelazzi D, Angeli A, Beck-Peccoz P. Hyperthyroidism due to a pituitary adenoma composed of two different cell types, one secreting alpha-subunit alone and another cosecreting alpha-subunit and thyrotropin. J Clin Endocrinol Metab. 1991;72:415–21.PubMedCrossRefGoogle Scholar
  96. Thompson LD, Seethala RR, Muller S. Ectopic sphenoid sinus pituitary adenoma (ESSPA) with normal anterior pituitary gland: a clinicopathologic and immuno-phenotypic study of 32 cases with a comprehensive review of the english literature. Head Neck Pathol. 2012;6:75–100.PubMedPubMedCentralCrossRefGoogle Scholar
  97. Tong A, Xia W, Qi F, Jin Z, Yang D, Zhang Z, Li F, Xing X, Lian X. Hyperthyroidism caused by an ectopic thyrotropin-secreting tumor of the nasopharynx: a case report and review of the literature. Thyroid. 2013;23:1172–7.PubMedCrossRefGoogle Scholar
  98. Tritos NA, Eppakayala S, Swearingen B, Hedley-Whyte ET, Miller KK, Nachtigall LB, Grinspoon SK, Biller BM, Klibanski A. Pathologic and clinical features of pituitary adenomas showing TSH immunoreactivity. Pituitary. 2013;16:287–93.PubMedCrossRefGoogle Scholar
  99. Ünlütürk U, Sriphrapradang C, Erdoğan MF, Emral R, Güldiken S, Refetoff S, Güllü S. Management of differentiated thyroid cancer in the presence of resistance to thyroid hormone and TSH-secreting adenomas: a report of four cases and review of the literature. J Clin Endocrinol Metab. 2013;98:2210–7.PubMedPubMedCentralCrossRefGoogle Scholar
  100. Varsseveld NC, Bisschop PH, Biermasz NR, Pereira AM, Fliers E, Drent ML. A long-term follow-up study of eighteen patients with thyrotrophin-secreting pituitary adenomas. Clin Endocrinol. 2014;80:395–402.CrossRefGoogle Scholar
  101. Wallace IR, Healy E, Cooke RS, Ellis PK, Harper R, Hunter SJ. TSH-secreting pituitary adenoma: benefits of pre-operative octreotide. Endocrinol Diabetes Metab Case Rep. 2015;2015:150007.PubMedPubMedCentralGoogle Scholar
  102. Wang Q, Lu XJ, Sun J, Wang J, Huang CY, Wu ZF. Ectopic suprasellar thyrotropin-secreting pituitary adenoma: case report and literature review. World Neurosurg. 2016;95:617.e13–8.CrossRefGoogle Scholar
  103. Watanabe K, Kameya T, Yamauchi A, Yamamoto N, Kuwayama A, Takei I, Maruyama H, Saruta T. Thyrotropin-producing microadenoma associated with pituitary resistance to thyroid hormone. J Clin Endocrinol Metab. 1993;76:1025–30.PubMedGoogle Scholar
  104. Webster J, Peters JR, John R, Smith J, Chan V, Hall R, Scanlon MF. Pituitary stone: two cases of densely calcified thyrotropin-secreting pituitary adenomas. Clin Endocrinol. 1994;40:137–43.CrossRefGoogle Scholar
  105. Yamada S, Fukuhara N, Horiguchi K, Yamaguchi-Okada M, Nishioka H, Takeshita A, Takeuchi Y, Ito J, Inoshita N. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases. J Neurosurg. 2014;121: 1462–73.PubMedCrossRefGoogle Scholar
  106. Yovos JG, Falko JM, O’Dorisio TM, Malarkey WB, Cataland S, Capen CC. Thyrotoxicosis and a thyrotropin-secreting pituitary tumor causing unilateral exophthalmos. J Clin Endocrinol Metab. 1981;53:338–43.PubMedCrossRefGoogle Scholar
  107. Zuniga S, Mendoza V, Espinoza IF, Zarate A, Mason M, Mercado M. A plurihormonal TSH-secreting pituitary microadenoma: report of a case with an atypical clinical presentation and transient response to bromocriptine therapy. Endocr Pathol. 1997;8:81–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Paolo Beck-Peccoz
    • 1
  • Claudia Giavoli
    • 2
  • Giulia Rodari
    • 2
  • Andrea Lania
    • 3
  1. 1.University of MilanMilanItaly
  2. 2.Endocrinology and Metabolic Diseases Unit, Department of Clinical Sciences and Community HealthUniversity of Milan, Fondazione IRCCS Cà Granda, Ospedale Maggiore PoliclinicoMilanItaly
  3. 3.Department of Biomedical Sciences, Humanitas University and Endocrinology UnitHumanitas Research HospitalRozzanoItaly

Personalised recommendations